Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04416984
PHASE1/PHASE2

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Sponsor: Allogene Therapeutics

View on ClinicalTrials.gov

Summary

This is a single-arm, open label, multicenter Phase 1/2 study evaluating ALLO-501A in adult subjects with R/R LBCL and CLL/SLL. The purpose of the ALPHA2 study is to assess the safety, efficacy, and cell kinetics of ALLO-501A in adults with relapsed or refractory large B-cell lymphoma and assess the safety of ALLO-501A in adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.

Official title: A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

160

Start Date

2020-05-21

Completion Date

2029-05

Last Updated

2026-03-04

Healthy Volunteers

No

Interventions

GENETIC

ALLO-501A

ALLO-501A is an allogeneic CAR T cell therapy targeting CD19

BIOLOGICAL

ALLO-647

ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

DRUG

Fludarabine

Chemotherapy for lymphodepletion

DRUG

Cyclophosphamide

Chemotherapy for lymphodepletion

Locations (29)

Banner MD Anderson Cancer Center

Gilbert, Arizona, United States

Mayo Clinic Hospital

Phoenix, Arizona, United States

City of Hope

Duarte, California, United States

UCLA Medical Center

Los Angeles, California, United States

Stanford Cancer Institute

Palo Alto, California, United States

Colorado Blood Cancer Institute

Denver, Colorado, United States

Yale School of Medicine

New Haven, Connecticut, United States

University of Miami

Miami, Florida, United States

Advent Health

Orlando, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

Northside Hospital - Atlanta

Atlanta, Georgia, United States

Augusta University

Augusta, Georgia, United States

Loyola University Medical Center

Maywood, Illinois, United States

Norton Cancer Institute

Louisville, Kentucky, United States

Karmanos Cancer Institute

Detroit, Michigan, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Providence Portland Medical Center

Portland, Oregon, United States

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States

Avera Medical

Sioux Falls, South Dakota, United States

Vanderbilt Ingram Cancer Center

Nashville, Tennessee, United States

St. David's South Austin Medical Center

Austin, Texas, United States

Texas Oncology

Dallas, Texas, United States

MD Anderson Cancer Center - University of Texas

Houston, Texas, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Princess Alexandra Hospital

Woolloongabba, Queensland, Australia

Monash Medical Centre

Clayton, Victoria, Australia

St. Vincent's Hospital Melbourne

Fitzroy, Victoria, Australia

QEII Health Sciences Centre-VG Site

Halifax, Nova Scotia, Canada

CHU de Québec -Université Laval; Hôpital de l'Enfant-Jésus

Québec, Quebec, Canada